These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 24343765)

  • 1. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues.
    Bergvall T; Norén GN; Lindquist M
    Drug Saf; 2014 Jan; 37(1):65-77. PubMed ID: 24343765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports.
    Wakao R; Taavola H; Sandberg L; Iwasa E; Soejima S; Chandler R; Norén GN
    Drug Saf; 2019 Dec; 42(12):1487-1498. PubMed ID: 31559542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Data-Driven Identification of Factors That Influence the Quality of Adverse Event Reports: 15-Year Interpretable Machine Learning and Time-Series Analyses of VigiBase and QUEST.
    Choo SM; Sartori D; Lee SC; Yang HC; Syed-Abdul S
    JMIR Med Inform; 2024 Apr; 12():e49643. PubMed ID: 38568722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The quality assessment of the Japanese Adverse Drug Event Report database using vigiGrade.
    Tsuchiya M; Obara T; Miyazaki M; Noda A; Takamura C; Mano N
    Int J Clin Pharm; 2020 Apr; 42(2):728-736. PubMed ID: 32020439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of probabilistic method to detect duplicate individual case safety reports.
    Tregunno PM; Fink DB; Fernandez-Fernandez C; Lázaro-Bengoa E; Norén GN
    Drug Saf; 2014 Apr; 37(4):249-58. PubMed ID: 24627310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
    Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
    Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of completeness for spontaneous reporting of disease-modifying therapies in multiple sclerosis.
    Araujo AGS; Lucchetta RC; Tonin FS; Pontarolo R; Borba HHL; Wiens A
    Expert Opin Drug Saf; 2021 Jun; 20(6):735-740. PubMed ID: 33641547
    [No Abstract]   [Full Text] [Related]  

  • 8. Paediatric safety signals identified in VigiBase: Methods and results from Uppsala Monitoring Centre.
    Star K; Sandberg L; Bergvall T; Choonara I; Caduff-Janosa P; Edwards IR
    Pharmacoepidemiol Drug Saf; 2019 May; 28(5):680-689. PubMed ID: 30767342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring Completeness of Adverse Event Reports as a Tool for Signal Detection in Pharmacovigilance.
    Lee I; Jokinen JD; Crawford SY; Calip GS; Kilpatrick RD; Lee TA
    Ther Innov Regul Sci; 2021 Jan; 55(1):142-151. PubMed ID: 32720297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The completeness of adverse drug reaction reports in South Africa: An analysis in VigiBase®.
    Matlala MF; Lubbe MS; Steyn H
    Afr J Prim Health Care Fam Med; 2023 Jan; 15(1):e1-e9. PubMed ID: 36744452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of completeness of suspected adverse drug reaction reports submitted to the mexican national pharmacovigilance centre: a cross-sectional period-prevalence study.
    Sánchez-Sánchez B; Altagracia-Martínez M; Kravzov-Jinich J; Moreno-Bonett C; Vázquez-Moreno E; Martínez-Núñez JM
    Drug Saf; 2012 Oct; 35(10):837-44. PubMed ID: 22924896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in Adverse Event Reporting Before and After the Introduction of the Med Safety App in Nigeria.
    Elemuwa UG; Bitrus F; Oreagba IA; Osakwe AI; Abiodun AS; Onu K; Abubakar A; Faniyi AE; Etuk V; Yuah D; Momodu R; Adeyeye CM
    Pharmaceut Med; 2024 May; 38(3):251-259. PubMed ID: 38705932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase.
    Star K; Norén GN; Nordin K; Edwards IR
    Drug Saf; 2011 May; 34(5):415-28. PubMed ID: 21513364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase.
    Strandell J; Caster O; Bate A; Norén N; Edwards IR
    Drug Saf; 2011 Mar; 34(3):253-66. PubMed ID: 21332249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study.
    Durrieu G; Jacquot J; Mège M; Bondon-Guitton E; Rousseau V; Montastruc F; Montastruc JL
    Drug Saf; 2016 Dec; 39(12):1189-1195. PubMed ID: 27688025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using VigiBase to Identify Substandard Medicines: Detection Capacity and Key Prerequisites.
    Juhlin K; Karimi G; Andér M; Camilli S; Dheda M; Har TS; Isahak R; Lee SJ; Vaughan S; Caduff P; Norén GN
    Drug Saf; 2015 Apr; 38(4):373-82. PubMed ID: 25687792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Analysis of Information Provided in German Adverse Drug Reaction Reports Sent by Physicians, Pharmacists and Consumers.
    Christ P; Dubrall D; Schmid M; Sachs B
    Drug Saf; 2023 Dec; 46(12):1363-1379. PubMed ID: 37987966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantity is not enough: completeness of suspected adverse drug reaction reports in Spain-differences between regional pharmacovigilance centres and pharmaceutical industry.
    Fernandez-Fernandez C; Lázaro-Bengoa E; Fernández-Antón E; Quiroga-González L; Montero Corominas D
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1175-1181. PubMed ID: 32447435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase.
    Sandberg L; Taavola H; Aoki Y; Chandler R; Norén GN
    Drug Saf; 2020 Oct; 43(10):999-1009. PubMed ID: 32564242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
    Trippe ZA; Brendani B; Meier C; Lewis D
    Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.